题名 | Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD |
作者 | Tang, Liang-Jie1; Ma, Hong-Lei1; Eslam, Mohammed2,3; Wong, Grace Lai-Hung4,5; Zhu, Pei-Wu6; Chen, Sui-Dan7; Leeming, Diana Julie8; Karsdal, Morten8; Li, Gang1; Huang, Ou-Yang1; Leung, Howard Ho-Wai9; Zhou, Yu-Jie10; Feng, Qian11; Jiang, Pei12; Gao, Li-Mei12; Byrne, Christopher D.13; Targher, Giovanni14,15; George, Jacob2,3; Wong, Vincent Wai-Sun4,5; Zheng, Ming-Hua1,16,17
|
发表期刊 | METABOLISM-CLINICAL AND EXPERIMENTAL 影响因子和分区 |
语种 | 英语 |
原始文献类型 | Article |
关键词 | Metabolic dysfunction-associated fatty liver disease N-terminal propeptide of type 3 collagen ADAPT Fibrosis staging |
其他关键词 | FATTY LIVER-DISEASE ; HEPATOCELLULAR-CARCINOMA ; CIRRHOSIS ; VARIABILITY ; PREDICT ; SYSTEM ; INDEX ; NAFLD |
摘要 | Background: With metabolic dysfunction-associated fatty liver disease (MAFLD) incidence and prevalence increasing, it is necessary to identify patients with advanced fibrosis (F3-F4 stages). We evaluated the performance of new biomarkers and algorithms for diagnosing advanced fibrosis in an Asian population. Methods: Data from two Asian cohorts (including 851 biopsy-proven MAFLD [578 from Wenzhou, 273 from Hong Kong]) were studied. The association between N-terminal propeptide of type 3 collagen (PRO-C3) and the histologic stage of liver fibrosis was analyzed by multivariable linear regression. The area under the receiver operating characteristic curve (AUROC) was used to test the diagnostic performance of serum PRO-C3 and the ADAPT score for advanced fibrosis and compared them to other established non-invasive tests. Results: Serum PRO-C3 levels increased progressively across liver fibrosis stages and correlated with advanced fibrosis (P < 0.001). The ADAPT score had an AUROC of 0.865 (95% confidence interval 0.829-0.901) for advanced fibrosis; the accuracy, sensitivity and negative predictive values were 81.4%, 82.2% and 96.1%, respectively. This result was better compared to that of PRO-C3 alone or other non-invasive fibrosis biomarkers (aspartate aminotransferase-to-platelet ratio index, Fibrosis-4, BARD, and NAFLD fibrosis score). In subgroup analyses (including sex, age, diabetes, NAFLD activity score, body mass index or serum alanine aminotransferase levels), the ADAPT score had good diagnostic performance. Conclusion: PRO-C3 and the ADAPT score reliably exclude advanced fibrosis in MAFLD patients and reduce the need for liver biopsy. (c) 2021 Elsevier Inc. All rights reserved. |
资助项目 | National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [82070588] ; High Level Creative Talents from Department of Health of Zhejiang Province [S2032102600032] ; Project of New Century 551 Talent Nurturing in Wenzhou ; School of Medicine, University of Verona, Verona, Italy ; Southampton NIHR Biomedical Research Centre [IS-BRC-20004] ; Chinese University of Hong KongChinese University of Hong Kong [2020.045] ; Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney ; National Health and Medical Research Council of Australia (NHMRC)National Health and Medical Research Council of Australia [APP1053206, APP1196492, APP2001692, APP1107178, APP1108422] |
出版者 | W B SAUNDERS CO-ELSEVIER INC |
出版地 | PHILADELPHIA |
ISSN | 0026-0495 |
EISSN | 1532-8600 |
卷号 | 128页码:154958 |
DOI | 10.1016/j.metabol.2021.154958 |
页数 | 7 |
WOS类目 | Endocrinology & Metabolism |
WOS研究方向 | Endocrinology & Metabolism |
WOS记录号 | WOS:000754032000004 |
收录类别 | SCIE ; PUBMED ; SCOPUS |
发表日期 | 2022-03 |
URL | 查看原文 |
Pubmed记录号 | 34958817 |
Scopus记录号 | 2-s2.0-85122093125 |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | https://kms.wmu.edu.cn/handle/3ETUA0LF/20577 |
专题 | 检验医学院(生命科学学院、生物学实验教学中心) 附属第一医院_消化内科 基础医学院(机能实验教学中心)_病理学与病理生理学系 |
通讯作者 | Wong, Vincent Wai-Sun; Zheng, Ming-Hua |
作者单位 | 1.Wenzhou Med Univ, MAFLD Res Ctr, Dept Hepatol, Affiliated Hosp 1, 2 Fuxue Lane, Wenzhou 325000, Peoples R China; 2.Westmead Hosp, Storr Liver Ctr, Westmead Inst Med Res, Westmead, NSW, Australia; 3.Univ Sydney, Sydney, NSW, Australia; 4.Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China; 5.Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Peoples R China; 6.Wenzhou Med Univ, Dept Lab Med, Affiliated Hosp 1, Wenzhou, Peoples R China; 7.Wenzhou Med Univ, Dept Pathol, Affiliated Hosp 1, Wenzhou, Peoples R China; 8.Nordic Biosci Biomarkers & Res AS, Herlev, Denmark; 9.Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China; 10.Shanghai Jiao Tong Univ, Renji Hosp, Sch Med,Key Lab Gastroenterol & Hepatol,Minist Hl, Shanghai Inst Digest Dis,Div Gastroenterol & Hepa, Shanghai, Peoples R China; 11.Wenzhou Med Univ, Dept Gastroenterol, Affiliated Hosp 1, Wenzhou, Peoples R China; 12.Fosun Diagnost Shanghai Co Ltd, Shanghai, Peoples R China; 13.Southampton Gen Hosp, Univ Hosp Southampton, Southampton Natl Inst Hlth Res, Biomed Res Ctr, Southampton, Hants, England; 14.Univ Verona, Dept Med, Sect Endocrinol Diabet & Metab, Verona, Italy; 15.Azienda Osped Univ Integrata Verona, Verona, Italy; 16.Wenzhou Med Univ, Inst Hepatol, Wenzhou, Peoples R China; 17.Key Lab Diag & Treatment Dev Chron Liver Dis Zhej, Wenzhou, Peoples R China |
第一作者单位 | 温州医科大学 |
通讯作者单位 | 温州医科大学 |
第一作者的第一单位 | 温州医科大学; 温州医科大学 |
推荐引用方式 GB/T 7714 | Tang, Liang-Jie,Ma, Hong-Lei,Eslam, Mohammed,et al. Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD[J]. METABOLISM-CLINICAL AND EXPERIMENTAL,2022,128:154958. |
APA | Tang, Liang-Jie., Ma, Hong-Lei., Eslam, Mohammed., Wong, Grace Lai-Hung., Zhu, Pei-Wu., ... & Zheng, Ming-Hua. (2022). Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. METABOLISM-CLINICAL AND EXPERIMENTAL, 128, 154958. |
MLA | Tang, Liang-Jie,et al."Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD".METABOLISM-CLINICAL AND EXPERIMENTAL 128(2022):154958. |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论